Expanding Partnerships Magnus has rapidly expanded health system partnerships across 14 states with notable institutions including Cleveland Clinic, UPMC, HCA Healthcare, UTHealth Houston, Houston Methodist, Dartmouth-Hitchcock, Sutter Health, and OhioHealth, presenting a wide network for upsell of SAINT neuromodulation services and integration opportunities.

Strategic Growth Regions The multi-state expansion signals ready-made entry points in large healthcare markets; sales efforts can target system-wide deployments, enterprise agreements, and regional procurement partnerships to accelerate SAINT adoption.

Milestone Credibility With FDA Breakthrough Device Designation and 510(k) clearance for MDD, Magnus demonstrates regulatory credibility and a validated treatment option, enabling persuasive conversations with hospital committees, physicians, and purchasing teams.

Revenue and Funding Strength Current revenue band and substantial funding position Magnus for scale, suggesting capacity to support larger contract negotiations, installation pipelines, and expanded service/support packages for health systems.

Technology & Data Readiness Existing tech stack and cloud-based infrastructure indicate readiness for enterprise-grade deployment, data integration, and remote monitoring; opportunities exist to offer compliant IT/ops integration, analytics, and outcomes tracking services to health systems.